Trial Profile
Evaluating the effects of carbidopa/levodopa/entacapone on motor function and quality of life in patients with Parkinson's disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Levodopa/carbidopa/entacapone (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Novartis
- 02 May 2009 Primary endpoint results presented at the 61st Annual Meeting of the American Academy of Neurology
- 18 Jul 2008 Status changed from in progress to completed, from clinicaltrials.gov record.
- 10 Jun 2008 Status change from recruiting to in progress, according to clinicaltrials.gov.